top of page
LA1_CD68op520_CD3_op570_CD8_op690_panCKAF750_20X -10.bmp

TruTumor Culture

 Preserving native spatial contexture in human tumor microenvironment

 Representing tumor heterogeneity

 Simultaneous comparison of multiple therapies for every patient tumor

 Orthogonal assays to assess response

 panCK CD8 CD3 CD68 Nucleus

Farcast proprietary image 

Farcast Human Tumor Microdynamics Platform

Farcast's living human tumor technology harvests fresh human tumors, and uses proprietary methods to fragment and culture them ex-vivo


Preservation of the entire tumor architecture along with near native functional and spatial fidelity enables the evaluation of treatment responses in truly biorepresentative human tumor microenvironments

Multimodal microdynamics "big data" is combined with sophisticated AI (artificial intelligence) to mine highly precise treatment response biosignatures

The Farcast system leads to higher precision compared to any conventional simplistic tumor models and helps understand the full complexities of human cancer

iStock-1385929874.png

TruNet

Trusted relationships with network of global cancer centers for processing of multi-population tumor samples

iStock-1385930831.png

TruSign

Biosignatures for precise understanding and predictability of treatments from mining "tumor microdynamics big data" with AI

Website Banner Farcast Bio.png

WE KNOW HUMAN TUMORS INSIDE OUT

 Precision-Guidance For Therapeutics And Diagnostics Development

Home
AACR ANNUAL 2023: Simultaneous comparison of response to two different anti-PD1 drugs in the same patient using a human tumor histo-culture platform

AACR_Poster_4568_Farcast_RCC_edited.jpg
AACR ANNUAL 2023: Can TKI failed patients be rescued with anti-PD1 Therapy?

SITC_annual_2022_edited_edited.jpg
37TH ANNUAL SITC 2022: 
Demonstrating the role of spatial contexture in determining response to immune check point inhibitors using a tumor histo-culture platform
bottom of page